New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For AVEO;ODP;RAD;AMAT;NAVB From The Last 14 Days
Check below for free stories on AVEO;ODP;RAD;AMAT;NAVB the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 24, 2014
16:09 EDTRADRite Aid names Darren Karst as executive VP, CFO
Subscribe for More Information
16:05 EDTRADRoundy's CFO Karst leaves for Rite-Aid, names Michael Turzenski as CFO
Roundy’s (RNDY) announced that Darren Karst, Roundy’s executive VP and CFO will be leaving the company to join Rite Aid (RAD) as its executive VP and CFO. Karst will remain with Roundy’s through August 9. Michael Turzenski, currently Roundy’s group VP and Chief Accounting Officer, has been appointed group VP, CFO by Roundy’s board. Turzenski has served as group VP, Chief Accounting Officer since February 2012. Turzenski joined Roundy’s in 2007 as VP, controller.
06:02 EDTAMATApplied Materials implied volatility of 38 at upper end of index mean range
July 23, 2014
05:53 EDTAMATStocks with implied volatility movement; IP AMAT
Subscribe for More Information
July 22, 2014
12:53 EDTAMATApplied Materials drops following report of opposition to merger
Subscribe for More Information
12:19 EDTAMATApplied Materials merger report 'pure speculation,' says Stifel
Subscribe for More Information
10:29 EDTAMATApplied Materials weakness a buying opportunity, says ISI Group
Subscribe for More Information
09:47 EDTAMATApplied Materials sees strong opposition to merger in China, DealReporter says
The proposed merger of Applied Materials (AMAT) with Tokyo Electron is facing strong opposition from Chinese regulators, said DealReporter, according to contacts.
July 16, 2014
07:37 EDTNAVBNavidea forms joint enterprise with Rheumco
Navidea announced that it has formed a joint enterprise with Essex Woodlands-backed Rheumco to develop and commercialize radiolabeled diagnostics and therapeutics for rheumatologic and arthritic diseases. The joint enterprise, called R-NAV, will combine Navidea’s proprietary Manocept CD206 macrophage targeting platform and Rheumco’s proprietary Tin-117m radioisotope technology to focus on leveraging the platforms across several indications with high unmet medical need. R-NAV will be initially funded primarily through a $4M investment from Infinity Capital III and other third-party private investors working closely with Essex Woodlands, and underpinning the technology contributions from Rheumco and Navidea. Navidea has committed an additional $1M to support R-NAV’s development efforts to be paid in equal installments over three years. In exchange for its cash, in-kind and technology contributions, Navidea has received both common units and Preferred Series A units of R-NAV and will initially own approximately 30% of the combined entity. Joint oversight of R-NAV is shared between Navidea, Rheumco, Infinity Capital III of Houston-based McRay Money Management, and the other investors. Navidea also has an option to acquire, at its sole discretion prior to Phase 3 clinical study, imaging products derived from the Manocept platform, and therapeutic products combining Manocept agents from Navidea with the Tin-117m technology for commercialization.
July 11, 2014
06:00 EDTRADStocks with implied volatility below IV index mean; RAD BBBY
Stocks with implied volatility below IV index mean; Rite Aid (RAD) 36, Bed Bath & Beyond (BBBY) 18 according to iVolatility.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use